Drugmakers cut down prices by 50% to enter China’s pharmaceutical market

Drug producers cut their drug costs in China by 50% because they want to gain access to the national insurance fund. Companies like AstraZeneca and BeiGene Ltd have accepted major chopping in their new and innovative drugs. Almost 119 medicines for treatment of diabetes, cancer etc have been included and covered in the national medical safety net. Some of the biggest drug makers are ready to sell drugs for the lowest prices only to enter the world’s second biggest pharmaceutical market which is China’s.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More